The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.
May 14th 2024
Closer monitoring of youth hypertension could lessen the disease in adults, reducing overall costs and morbidity related to cardiovascular disease (CVD), new research shows.
Iron Replacement Has No Impact on Disease Severity, Quality of Life in PAH
April 1st 2021Idiopathic pulmonary arterial hypertension (PAH) is associated with iron deficiency, which is in turn associated with worse functional capacity and survival in PAH; however, iron repletion by infusion provided no significant clinical benefit.
Read More
Survey Finds Unmet Needs Despite Good HRQOL for Patients With PAH
March 21st 2021Despite patients with pulmonary arterial hypertension reporting good quality of life and low symptom severity, functional limitations persisted, suggesting improvements to the patient experience are needed, according to researchers.
Read More
Patients With PAH Have Similar Incidence of COVID-19, but Potentially Worse Outcomes
March 18th 2021Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension had similar incidence of COVID-19, but the impact on clinical operations at the centers that treat these patients was substantial.
Read More
Newly Diagnosed Patients With PAH Benefit From Earlier Initiation of Therapy
March 7th 2021Patients with pulmonary arterial hypertension (PAH) who are treated with selexipag within 6 months of their diagnosis had a reduced risk of morbidity/mortality compared with patients who were treated longer than 6 months after diagnosis.
Read More
Pulmonary Arterial Capacitance Is a Strong Predictor of Mortality in PAH, PH-LHD
March 5th 2021Targeting pulmonary arterial capacitance or compliance can improve overall survival and quality of life in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension secondary to left heart disease (PH-LHD).
Read More
Understanding Mortality Risk in Pediatric Pulmonary Arterial Hypertension
February 26th 2021The study examined various factors used in an internationally developed risk stratification strategy to assess which ones had evidence of being significant in determining a child’s prognosis from the deadly disease.
Read More
Which Agents Are Linked to Drug- and Toxin-Induced PAH?
February 20th 2021In their recently published review, the researchers offer a detailed look at the drugs and toxins associated with drug- and toxin-induced pulmonary arterial hypertension (PAH), as various associations have come to light in recent decades.
Read More
A Roadmap for Managing Right Ventricular Failure in PH
February 19th 2021The researchers prefaced their study by highlighting that pulmonary arterial hypertension (PAH) and all forms of PH continue to be highly morbid and sometimes fatal, particularly in cases requiring hospitalization in the intensive care unit.
Read More
Machine Learning-Based Approach to CMR Imaging Analysis Proves Beneficial for PAH Diagnosis
February 5th 2021The approach, the researchers say, allows for rapid and accurate diagnosis of pulmonary arterial hypertension (PAH) by analyzing cardiac magnetic resonance (CMR) images without manual image segmentation.
Read More
Researchers Highlight Progress, Remaining Unknowns in Genetics of PAH
January 30th 2021As up to 1 in 3 patients with pulmonary arterial hypertension have unknown explanations for their disease and its pathobiology, a team of researchers is exploring the genetic architecture of pulmonary arterial hypertension (PAH).
Read More
Ensuring a Path of Success for Drug Repurposing in PAH
January 14th 2021Among the viewpoints offered by the authors to overcome barriers in solving unmet needs in pulmonary arterial hypertension (PAH) are preclinical pipelines for drug repurposing, working around challenges in early-stage trial design, and refining target selection and demonstration of engagement.
Read More
Researchers Identify Predictors of Pulmonary Hypertension Among Patients With MPNs
December 29th 2020Survival among patients with myeloproliferative neoplasm (MPN)–associated pulmonary hypertension (PH) is generally short, although the true prevalence of PH among these patients is poorly understood.
Read More
Studies Highlight Multiple Underlying Etiologies of PAH, Predictive Factors of PAA
December 10th 2020A group of researchers published their research on the various underlying etiologies of pulmonary arterial hypertension (PAH), as well as predictive factors of pulmonary artery aneurysms (PAAs).
Read More
A Look at the Use of Echocardiography to Assess Macitentan Effects, Predict Mortality in PAH
December 5th 2020Two studies presented at CHEST 2020 assessed the impact of macitentan on cardiac function in pulmonary arterial hypertension (PAH) and determined what role reproducible exercise echocardiographic parameters have in predicting survival.
Read More
Selexipag Improves Outcomes in Patients With CTD-PAH
December 3rd 2020Use of selexipag in patients with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) resulted in outcomes similar to those seen in patients with idiopathic PAH, despite the traditionally poorer prognosis of CTD-PAH.
Read More